The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose
Main finding · Receipt of a second zoledronic acid doseResult — go to the resultHazard ratio 1.50 95% CI 1.31–1.71Authors' conclusion
In contrast to patients in pivotal trials, most patients receiving zoledronic acid had prior osteoporosis pharmacotherapy. Patients with prior oral bisphosphonate use had higher rates of receiving a second dose.
Study context
- Population
- Older patients initiating publicly funded zoledronic acid for osteoporosis, Ontario, Canada, 10/2006–10/2021, followed until 10/2022median age 77, 81% female
- Participants
- 3,308 patients
- Exposure
- Prior osteoporosis treatment history vs no history
- Outcome
- Receipt of a second zoledronic acid infusion
Methodological detailspopulation-based healthcare administrative data, Cox proportional hazards models
- Population-based healthcare administrative data
- Cox proportional hazards models
Main finding
Receipt of a second zoledronic acid dose
Hazard ratio
1.50
95% CI 1.31–1.71
By group
Oral bisphosphonatesvs No history
HR 1.50 (95% CI 1.31–1.71)
As reported in the abstract
- Overall, received a second infusion
- 31%
Observational data: associations, not effects.
Original publication
The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose. Osteoporos Int. Published 4 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →